SYMBIOTEC — Symbiotec Pharmalab Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Annual income statement for Symbiotec Pharmalab, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	PROSPECTUS	PROSPECTUS
Standards:	IAS	IAS	IAS	IAS
Status:	Final	Final	Final	Final
Revenue
Total Revenue	11,330	14,325	15,031	17,383
Cost of Revenue
Gross Profit	2,747	3,952	4,542	5,537
Selling / General / Administrative Expenses
Depreciation and Amortization
Operating Interest Expense / Income
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	10,460	11,647	11,835	13,609
Operating Profit	870	2,678	3,196	3,774
Total Net Non Operating Interest Income / Expense
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	765	2,620	2,940	3,067
Provision for Income Taxes
Net Income After Taxes	470	2,001	1,936	2,198
Minority Interest
Net Income Before Extraordinary Items
Net Income	469	2,004	1,936	2,198
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	469	2,004	1,936	2,198
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	7.3	31.2	30.2	33.8